To compile the report, Moody’s analyzed data drug companies presented at the American Society of Clinical Oncology meeting held June 3 to June 7 in Chicago.
Here are four report findings.
- Moody’s predicts breast cancer and lung cancer will be the largest drivers of sales growth in 2017 and 2018.
- Merck, AstraZeneca, Eli Lilly and Incyte Corp., will benefit the most from this growth, according to the report.
- Roche, Pfizer and Bristol-Myers Squibb will experience increasing competitive pressures in the future cancer drug market. However, these drugmakers will still benefit from ongoing development of new oncology treatments.
- Combination regimens will grow into increasingly important drug therapies.
More articles on supply chain:
Across enemy lines: Insurer recruits former drug reps to push more generics
Joslin Diabetes Center affiliate HSHS Medical Group to offer MiniMed insulin pump
FDA OKs Claret Medical’s stroke prevention device
